FDA Approves IGALMI as First At-Home Acute Treatment for Mental Health Crisis
The U.S. FDA has cleared IGALMI®, making it the first-ever at-home treatment for acute agitation in adults. This drug is a major development for patients managing serious conditions like schizophrenia and bipolar disorder.
- 5 sources report it: thestar.com, biospace.com, managedhealthcareexecutive.com, ajmc.com and 1 more.
- The source published it on Nov 16, 2026 at 5:01 AM.
Nothing open. Every check passed.
>The U.S. FDA has officially approved IGALMI®, marking it as the first at-home acute treatment for specific mental health disorders.<br><br>The drug is approved for treating agitation associated with several severe conditions in adults. These diagnoses include Schizophrenia, Schizoaffective Disorder, and both Bipolar I and Bipolar II Disorder.<br><br>This approval gives patients a new, accessible option for managing acute agitation outside of a hospital setting.
entities
IGALMI
U.S. FDA
crypto_tag
null
TopicsIGALMI · U.S. FDA
Written by AI from verified reporting.

